Sapphiros AiBio

Sapphiros AI Bio is a biotechnology research company focused on the field of regenerative medicine and allogeneic cell therapy. The organization utilizes a proprietary biobank containing over 85,000 fully consented human donor cell lines to research and develop therapies aimed at tissue repair, with an initial therapeutic program dedicated to regenerating damaged cartilage. Its platform integrates molecular biology and informatics to model diseases, generate human tissues, and engineer human cells, bridging the gap between research and clinical application.

The company's work in regenerative medicine addresses the need for effective, off-the-shelf therapeutic treatments for various indications and conditions. By leveraging its vast array of genetic variations in its cell bank, Sapphiros AI Bio aims to advance the understanding of human biology and disease to impact healthcare outcomes. While the company is involved in ongoing preclinical development and research, it operates as a distinct entity from the consumer diagnostics platform company Sapphiros.